Four clinical trials have been undertaken to evaluate the safety of active surveillance for low-risk DCIS, defined as grade I or II and, in one study, oestrogen receptor-positive and HER2-negative [37–41]. The gene discussed is ERBB2; the disease is ductal breast carcinoma in situ.